Document Type : Review Article
Authors
1
Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Gesr El Suez st, PO 11786, Cairo, Egypt
2
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, African Union Organization Street, Cairo 11566, Egypt
3
Department of Pharmacology and Toxicology, Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Gesr El Suez st, PO 11786 Cairo, Egypt Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University,
4
Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Gesr El Suez st, PO 11786, Cairo, Egypt Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr
Abstract
As the most prevalent type of dementia with a high rate of mortality and disability, Alzheimer's disease (AD) poses serious and growing global issues. Its etiology is complex, serious and multifaceted, resulting from a confluence of environmental, genetic, and age variables. The cholinergic, amyloid, tau protein, oxidative stress, and inflammatory hypotheses are some of the theories that now underlie our understanding of AD pathology. However, more clarification and verification are needed to identify the main reasons causing AD and to understand how these clinical features interact. The cholinergic hypothesis states that Alzheimer's disease impairs the brain's cholinergic function, which results in decreased levels of the neurotransmitter acetylcholine (ACh) in the cortical and hippocampus areas. Thus, ACh level elevation is one of the main goals of current pharmaco-therapeutic strategies for decreasing progression of AD. Based on the aforementioned findings, this article provides an overview of the latest progress in the development of powerful novel AChE inhibitors.
Keywords
Main Subjects
)
View on SCiNiTO